{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Breast+Carcinoma&page=35",
    "query": {
      "condition": "Stage I Breast Carcinoma",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 1213,
    "total_pages": 122,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Breast+Carcinoma&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Breast+Carcinoma&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T01:02:38.972Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06297265",
      "title": "Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anatomic Stage 0 Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Localized Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lymphedema Management",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Adjuvant breast radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2024-05-24",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06297265"
    },
    {
      "nct_id": "NCT00531271",
      "title": "ABI-008 Trial in Patients With Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ABI-008 (nab-docetaxel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2007-11-01",
      "completion_date": "2008-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-11-14",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00531271"
    },
    {
      "nct_id": "NCT04549571",
      "title": "Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anatomic Stage 0 Breast Cancer AJCC v8",
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Anatomic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage 0 Breast Cancer AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Decision Aid iCanDecide - ESE website",
          "type": "OTHER"
        },
        {
          "name": "Decision Aid iCanDecide - S website",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Training",
          "type": "OTHER"
        },
        {
          "name": "Media Intervention",
          "type": "OTHER"
        },
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 543,
      "start_date": "2021-02-16",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 27,
      "location_summary": "Vallejo, California • Newark, Delaware • Rehoboth Beach, Delaware + 23 more",
      "locations": [
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Rehoboth Beach",
          "state": "Delaware"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04549571"
    },
    {
      "nct_id": "NCT04893109",
      "title": "ATEMPT 2.0: Adjuvant T-DM1 vs TH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab-emtansine",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab SC",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2021-06-16",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 53,
      "location_summary": "San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Glastonbury",
          "state": "Connecticut"
        },
        {
          "city": "Greenwich",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04893109"
    },
    {
      "nct_id": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2010-08",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183663"
    },
    {
      "nct_id": "NCT01869764",
      "title": "Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ductal Breast Carcinoma in Situ",
        "Lobular Breast Carcinoma in Situ",
        "Male Breast Cancer",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "omega-3 fatty acid",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2013-11",
      "completion_date": "2018-07",
      "has_results": true,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01869764"
    },
    {
      "nct_id": "NCT01650506",
      "title": "Study of Erlotinib and Metformin in Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 79 Years · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2012-07",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-08-30",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01650506"
    },
    {
      "nct_id": "NCT01552434",
      "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Castleman Disease",
        "Digestive System Carcinoma",
        "Erdheim-Chester Disease",
        "Lip and Oral Cavity Carcinoma",
        "Lymphangioleiomyomatosis",
        "Malignant Endocrine Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Male Reproductive System Neoplasm",
        "Malignant Neoplasm",
        "Malignant Respiratory Tract Neoplasm",
        "Malignant Thoracic Neoplasm",
        "Malignant Urinary System Neoplasm",
        "Mesothelial Neoplasm",
        "Metastatic Malignant Neoplasm",
        "Metastatic Urothelial Carcinoma",
        "Neurofibromatosis Type 2",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Digestive System Carcinoma",
        "Recurrent Female Reproductive System Carcinoma",
        "Recurrent Male Reproductive System Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Pharyngeal Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Malignant Neoplasm",
        "Soft Tissue Neoplasm",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Pharyngeal Cancer",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Pharyngeal Cancer",
        "Stage IVA Pharyngeal Cancer",
        "Stage IVB Pharyngeal Cancer",
        "Stage IVC Pharyngeal Cancer",
        "Thyroid Gland Neoplasm"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 154,
      "start_date": "2012-10-16",
      "completion_date": "2026-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552434"
    },
    {
      "nct_id": "NCT00724386",
      "title": "Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "1999-06",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-03-07",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00724386"
    },
    {
      "nct_id": "NCT03589339",
      "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiotherapy",
        "Immunotherapy",
        "Microsatellite Instability-High Solid Malignant Tumour",
        "Metastasis From Malignant Tumor of Liver",
        "Squamous Cell Carcinoma of Head and Neck",
        "Metastasis From Malignant Tumor of Cervix",
        "Metastatic Renal Cell Carcinoma",
        "Metastasis From Malignant Melanoma of Skin (Disorder)",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic NSCLC",
        "Metastasis From Malignant Tumor of Bladder (Disorder)"
      ],
      "interventions": [
        {
          "name": "NBTXR3",
          "type": "DRUG"
        },
        {
          "name": "SABR",
          "type": "RADIATION"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Nanobiotix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2019-01-16",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-18T01:02:38.972Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03589339"
    }
  ]
}